Biotechs Walking a Fine Line

tight

The Biotech sector has been a Wall Street darling for the last 5 years, the Nasdaq biotech index is up roughly 350% in that time frame.  I believe that the sector right now is in a precarious position, the $IBB and $XBI have come under a little pressure over the last week and a few stocks like $BLUE have sold off on what many believed was good news.

The $XBI $IBB and $NBI-X are all trading below their 20 day moving averages and below an ascending trend-line that started in October.  But, if you put all the chart stuff aside, I believe this sector has become an over loved sector that is not reacting to news or bouncing with the same gusto as it has in the past after multiple down days.  The sector has become so loved that what you hear now is– “people will never stop using drugs so these stocks really won’t go down” or “recession or no recession, regardless of what happens in the market doctors won’t stop prescribing drugs” etc… and while this might be true, at the end of the day stocks go up and down not up or down.

From a trading perspective, I would look to short the sector as close as possible to the 20 day moving average/ascending trend-line with a stop at their respective 52 week highs.

ibb

 

nbix

 

xbi

 

 

Sign Up For Free Updates

Zor Capital LLC is a New York based investment management firm, founded in 2011. Our goal is superior performance, with preservation of capital as our number one priority. Zor Capital manages separate accounts (both taxable and retirement) for accredited investors and institutions. This structure gives clients access to a hedge fund like strategy while maintaining 100% control of their accounts.  Managed Assets

$XBI, $BBH, $NBI-X,

Picture; Virginia Edu


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.


blog comments powered by Disqus